Edwards Lifesciences (EW)
(Delayed Data from NYSE)
$67.23 USD
-2.13 (-3.07%)
Updated Sep 17, 2024 04:00 PM ET
After-Market: $67.23 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$67.23 USD
-2.13 (-3.07%)
Updated Sep 17, 2024 04:00 PM ET
After-Market: $67.23 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth F Momentum F VGM
Zacks News
Bull of the Day: Edwards Lifesciences (EW)
by Tracey Ryniec
This medical innovator is a superstar stock.
Top Analyst Reports for Apple, Comcast & NVIDIA
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), Comcast Corporation (CMCSA) and NVIDIA Corporation (NVDA).
Edwards Lifesciences (EW) Recalls PASCAL's Guide Sheath
by Zacks Equity Research
Edwards Lifesciences (EW) issues a product recall for its guide sheath based on report from its urgent field safety notice.
Top & Flop ETFs of Last Week
by Sanghamitra Saha
Cocoa ETF was a hot trade last week while cannabis ETF lost the most.
Haemonetics (HAE) Grows on New Products, Robust Plasma Sales
by Zacks Equity Research
Haemonetics (HAE) witnesses a steady uptick in Plasma franchise, fueled by favorable price, volume and mix.
Will Edwards Lifesciences (EW) Gain on Rising Earnings Estimates?
by Zacks Equity Research
Edwards Lifesciences (EW) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Is Edwards Lifesciences (EW) a Solid Growth Stock? 3 Reasons to Think " Yes "
by Zacks Equity Research
Edwards Lifesciences (EW) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Penumbra's (PEN) Q3 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
Penumbra (PEN) witnessed strong growth across all geographies and product lines in Q3.
Dentsply (XRAY) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Dentsply (XRAY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
DexCom (DXCM) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
DexCom (DXCM) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Nevro (NVRO) Q3 Loss Narrower Than Expected, Revenues Up Y/Y
by Zacks Equity Research
Nevro (NVRO) launches the Senza Omnia SCS System commercially in the United States in Q3.
DexCom (DXCM) Earnings and Revenues Beat Estimates in Q3
by Zacks Equity Research
DexCom's (DXCM) Q3 earnings benefit from higher revenues, solid performing Sensor and Transmitter segments and strong 2019 outlook. However, contraction in gross margin remains a woe.
Glaukos (GKOS) Q3 Loss Narrower Than Expected, '19 View Up
by Zacks Equity Research
Glaukos' (GKOS) Q3 revenues surge year over year. Also, the company raises 2019 revenue guidance.
LHC Group (LHCG) Q3 Earnings Surpass Estimates, Revenues Lag
by Zacks Equity Research
LHC Group (LHCG) third-quarter results benefit from home health and hospice admissions and higher revenues.
Option Care Health (BIOS) Q3 Earnings Meet, Revenues Top
by Zacks Equity Research
Albeit Option Care Health (BIOS) is yet to reap material benefits from its merger-related synergies, the reporting of a positive gross margin in third-quarter results is encouraging for investors.
DENTSPLY SIRONA (XRAY) Beats on Q3 Earnings, Ups '19 View
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) gains from solid segmental contributions in Q3.
Cardinal Health (CAH) Q1 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Cardinal Health (CAH) Q1 results benefit revenue growth and strong segmental performance. However, contraction in gross margin remains a concern.
AmerisourceBergen (ABC) Q4 Earnings & Revenues Beat Estimates
by Zacks Equity Research
AmerisourceBergen's (ABC) Q4 earnings benefit from higher revenues, segmental growth and strong fiscal 2020 outlook.
Insulet (PODD) Beats on Q3 Earnings, Ups '19 Revenue View
by Zacks Equity Research
Insulet's (PODD) year-over-year improvement in Q3 revenues on the solid uptake of Omnipod system both in the United States and across international markets looks promising.
OPKO Health (OPK) Q3 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
OPKO Health (OPK) third-quarter results benefit from higher Product revenues and RAYALDEE prescription growth.
CVS Health (CVS) Beats on Q3 Earnings, Raises '19 EPS Guidance
by Zacks Equity Research
CVS Health's (CVS) strong year-over-year growth in the top line is aided by a robust performance at the Pharmacy Services segment.
HMS Holdings (HMSY) Q3 Earnings Top Estimates, Revenues Miss
by Zacks Equity Research
HMS Holdings' (HMSY) Q3 earnings benefit from higher revenues at Analytical Services unit and strong 2019 outlook.
Avanos (AVNS) Earnings and Revenues Miss Estimates in Q3
by Zacks Equity Research
Avanos (AVNS) third-quarter results benefit from higher revenues and strong segmental performance.
Inogen's (INGN) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Softness in domestic and international business-to-business revenues impact Inogen's (INGN) Q3 results.
DaVita (DVA) Earnings and Revenues Beat Estimates in Q3
by Zacks Equity Research
DaVita (DVA) raises guidance for 2019 following impressive Q3 results.